# 13386125

# CH \$40,00

### PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
Andreas Fritze	06/15/2010
Karine Corcelle	06/18/2010
Melinda Eniko Grubesa	07/02/2010

### **RECEIVING PARTY DATA**

Name:	NOVARTIS AG
Street Address:	Lichtstrasse 35
City:	Basel
State/Country:	SWITZERLAND
Postal Code:	4056

### PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13386125

# **CORRESPONDENCE DATA**

Fax Number: (973)781-8064 Phone: 8627788462

Email: pip\_inbox.phchbs@novartis.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Correspondent Name: Linda Adams

Address Line 1: Novartis Pharmaceuticals Corporation

Address Line 2: One Health Plaza

Address Line 4: East Hanover, NEW JERSEY 07936

ATTORNEY DOCKET NUMBER:	PAT053678-US-PCT
NAME OF SUBMITTER:	Linda Adams

Total Attachments: 8

source=53678\_US\_PCT\_assignment#page1.tif source=53678\_US\_PCT\_assignment#page2.tif source=53678\_US\_PCT\_assignment#page3.tif source=53678\_US\_PCT\_assignment#page4.tif source=53678\_US\_PCT\_assignment#page5.tif source=53678\_US\_PCT\_assignment#page6.tif source=53678\_US\_PCT\_assignment#page7.tif source=53678\_US\_PCT\_assignment#page8.tif





(joint)

# **ASSIGNMENT**

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, we
(1) Andreas Fritze, (2) Karine Corcelle and (3) Melinda Enikö Grubesa,
respectively residing at
(1) Novartis Pharma AG,
Postfach
4002 Basel
SWITZERLAND,
(2) Novartis Pharma AG
Postfach
4002 Basel
SWITZERLAND,
(3) Novartis Pharma AG
Postfach
4002 Basel
SWITZERLAND,
do hereby sell, assign and transfer to Novartis AG, a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, (hereinafter referred to as the "ASSIGNEE") and its successors, assigns and legal representatives, all of my right, title and interest for all countries of the world in and to (1) all of my inventions and discoveries described in the patent application(s) titled
Pharmaceutical Compositions
and filed in the United States Patent and Trademark Office on, 20 and accorded Application Number* and/or filed in the RO/EP on, 20 and accorded International Patent Application Number PCT/EP 2010/060470 *, (2) the patent application(s) identified in (1), (3) all national stages of any international patent application identified in (1), (4) all other patent applications in all countries and regions claiming the priority of the provisional or non-provisional patent application filed in the United States Patent and Trademark Office on 21 July 2009 and accorded Application Number 61/227141 and on 18 January 2010 and accorded Application Number 61/295884, (5) for all patent applications, all rights of priority based upon the United States patent application identified in (4) in all countries and regions under the Paris Convention for the Protection of Industrial Property, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application identified in (4) is a provisional patent application, under 35 USC 119(e) (including the right to file patent applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our names, at their election and in accordance with application or international patent application designating the United States identified in (1), any national stages of any international application identified in (1) and any patent applications within the scope of (4) (including further continuations and divisions such as but not limited to continuations of continuations and continuations of
continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2)-(4) and (6) hereinafter referred to collectively as "patent applications"), (7) all patents that are

granted on any of said patent applications, (8) all registrations and confirmations of, and importation certificates based upon, one or more of said patents and applications for such registrations, confirmations and importation certificates and (9) all reissues, renewals and extensions of said patents, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and

supplementary protection certificates based upon said patents and applications for such reissues, renewals,

extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE and their successors, assigns and legal representatives to the full ends of the terms for which said patents, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

\*We hereby authorize **ASSIGNEE** and their representatives to insert in this Assignment the filing date(s) and Application Number(s) of said patent application(s) when notified thereof.

And we hereby covenant and agree that we will, at any time, (i) upon the request, but at the expense, of **ASSIGNEE** or their successors, assigns or legal representatives execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, patent applications, patents, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates and applications within the scope of (8) and (9) in **ASSIGNEE** or their successors, assigns or legal representatives, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of **ASSIGNEE** or their successors, assigns or legal representatives execute all additional patent applications within the scope of (3), (4) and (6) and all applications within the scope of (8) or (9) and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of **ASSIGNEE** or their successors, assigns or legal representatives.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 15 day of June	, 20 <u>AQ</u>
1.4tre	L.S.
Andreas Fritze	
Executed this 18 day of 100	, 20 <u>′b</u> .
Toule	L.S.
Karine Corcelle	
Executed this day of	, 20
	1.0
Melinda Enikö Grubesa	L.S.

# Page 3

# **ACCEPTANCE OF ASSIGNMENT**

With reference to the Assignment to NOVARTIS AG of an invention entitled "Pharmaceutical Compositions" signed by Andreas Fritze, Karine Corcelle, Melinda Enikö Grubesa; this will certify that NOVARTIS AG accepts such Assignment.

**NOVARTIS AG** 

By:

June Violet Mentel

Sonja Bösch

Function:

Name:

**Duly Authorized Signatories** 

Date:

**PATENT** 

**REEL: 027566 FRAME: 0872** 

#### **Attestation**

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signatures attached heretofore are the genuine signatures of **Mr. Andreas Fritze**, citizen of Germany, residing in Lörrach, Germany; of **Ms. Karine Corcelle**, citizen of France, residing in Kembs, France.

I further certify that the signatures attached heretofore are the genuine signatures of Ms. June Violet Mentel, citizen of Grenchen/SO, Switzerland, residing in Arlesheim, Switzerland, and of Ms. Sonja Bösch, German citizen, residing in Pfaffenweiler, Germany, both acting for Novartis AG, in Basel, Switzerland, both as proxy holders, both with joint signature.

The suthenticity of the signature was established by means of comparison.

BACEL, Switzerland, this 18<sup>th</sup> (eighteenth) day of August 2010 (two thousand and ten)

M. Naehor, Wer

Dr. M. Staehelin

Leg.Prot.Nr. / 구38/2010



#### **ASSIGNMENT**

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, we (1) Andreas Fritze, (2) Karine Corcelle and (3) Melinda Enikö Grubesa, respectively residing at (1) Novartis Pharma AG, Postfach 4002 Basel SWITZERLAND, (2) Novartis Pharma AG **Postfach** 4002 Basel SWITZERLAND, (3) Novartis Pharma AG **Postfach** 4002 Basel SWITZERLAND. do hereby sell, assign and transfer to Novartis AG, a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, (hereinafter referred to as the "ASSIGNEE") and its successors, assigns and legal representatives, all of my right, title and interest for all countries of the world in and to (1) all of my inventions and discoveries described in the patent application(s) titled **Pharmaceutical Compositions** and filed in the United States Patent and Trademark Office on \_\_\_\_\_\_, 20\_ and accorded Application \* and/or filed in the RO/ 2P on 20 July , 2010 and accorded International Patent Application Number PCT/ EP 20 10/060490 \*, (2) the patent application(s) identified in (1), (3) all national stages of any international patent application identified in (1), (4) all other patent applications in all countries and regions claiming the priority of the provisional or non-provisional patent application filed in the United States Patent and Trademark Office on 21 July 2009 and accorded Application Number 61/227141 and on 18 January 2010 and accorded Application Number 61/295884, (5) for all patent applications, all rights of priority based upon the United States patent application identified in (4) in all countries and regions under the Paris Convention for the Protection of Industrial Property, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application identified in (4) is a provisional patent application, under 35 USC 119(e) (including the right to file patent applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our names, at their election and in accordance with applicable law in all countries and regions), (6) all continuations and divisions of any United States patent application or international patent application designating the United States identified in (1), any national stages of any international application identified in (1) and any patent applications within the scope of (4) (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2)-(4) and (6) hereinafter referred to collectively as "patent applications"), (7) all patents that are granted on any of said patent applications, (8) all registrations and confirmations of, and importation certificates based upon, one or more of said patents and applications for such registrations, confirmations

and importation certificates and (9) all reissues, renewals and extensions of said patents, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and

supplementary protection certificates based upon said patents and applications for such reissues, renewals,

## Page 2

extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said **ASSIGNEE** and their successors, assigns and legal representatives to the full ends of the terms for which said patents, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

\*We hereby authorize **ASSIGNEE** and their representatives to insert in this Assignment the filing date(s) and Application Number(s) of said patent application(s) when notified thereof.

And we hereby covenant and agree that we will, at any time, (i) upon the request, but at the expense, of ASSIGNEE or their successors, assigns or legal representatives execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, patent applications, patents, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates and applications within the scope of (8) and (9) in ASSIGNEE or their successors, assigns or legal representatives, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE or their successors, assigns or legal representatives execute all additional patent applications within the scope of (3), (4) and (6) and all applications within the scope of (8) or (9) and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE or their successors, assigns or legal representatives.

This Assignment is effective as from the earliest priority date as stated above.

Executed this	day of	, 20
		L. <u>S</u> .
Andreas Fritze		'
Executed this	day of	, 20
Karine Corcelle		_ L.S.
Executed this <u>62</u>	_day of July_	, 20 <b>_(</b> Ø
Executed this 62  Mulkfo  Melinda Enikö Grubes	ia V	L.S.

# Page 3

# **ACCEPTANCE OF ASSIGNMENT**

With reference to the Assignment to NOVARTIS AG of an invention entitled "Pharmaceutical Compositions" signed by Andreas Fritze, Karine Corcelle, Melinda Enikö Grubesa; this will certify that NOVARTIS AG accepts such Assignment.

**NOVARTIS AG** 

By:

Name:

June Violet Mentel

Sonja Bösch

Function:

**Duly Authorized Signatories** 

Date:

19 July 2010

PATENT

REEL: 027566 FRAME: 0876

#### **Attestation**

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signature attached heretofore is the genuine signature of Ms. Melinda Eniko Grubesa, citizen of Romania, residing in Basel, Switzerland.

I further certify that the signatures attached heretofore are the genuine signatures of Ms. June Violet Mentel, citizen of Grenchen/SO, Switzerland, residing in Arlesheim, Switzerland, and of Ms. Sonja Bösch, German citizen, residing in Pfaffenweiler, Germany, both acting for Novartis AG, in Basel, Switzerland, both as proxy holders, both with joint signature.

The authenticity of the signature was established by means of comparison.

BASEL, witzerland, this 18<sup>th</sup> (eighteenth) day of August 2010 (two thousand and ten)

M. Stacher, Note

Dr. M. Staehelin Notar

Leg.Prot.Nr. ハイスチャ2010

**PATENT** 

**REEL: 027566 FRAME: 0877** 

**RECORDED: 01/20/2012**